Autologous Bone Marrow Transplantation - Blog Science Connections

More documents

Recommendations

Info

Autologous Bone Marrow Transplantation PROCEEDINGS OF THE THIRD INTERNATIONAL SYMPOSIUM Edited By Karel A Dicke Gary Spitzer Sundar Jagannath and Guest Editors Marie Favrot William Peters The University of Texas M. D. Anderson Hospital and Tumor Institute at Houston
Page 1: Autologous Bone Marrow Transplantat
Page 6 and 7: Publication of these proceedings is
Page 9 and 10: Contents Preface xix Acknowledgment
Page 11 and 12: ABMT ix Double Unpurged Autologous
Page 13 and 14: ABMT xi Treating Advanced Hodgkin's
Page 15 and 16: ABMT xiii Repeated High-Dose Chemot
Page 17 and 18: ABMT xu Session V - Lung Cancer Det
Page 19 and 20: ABMT xuii Toxic Deaths After Autolo
Page 21: Preface The Proceedings of the Thir
Page 25: IA. Clinical Studies in First-Remis
Page 28 and 29: 4 AML in First Remission used in pa
Page 30 and 31: 6 AML in First Remission i 40- < 3
Page 33 and 34: BAVC Regimen and Autologous Bone Ma
Page 35 and 36: BAVC + ABMT in Patients With AML in
Page 37 and 38: BAVC + ABMT in Patients With AML in
Page 39 and 40: Use of Bone Marrow Incubated With M
Page 41 and 42: Purged ABMT in CR of Acute Leukemia
Page 47 and 48: Autologous Transplantation of Unpur
Page 49 and 50: First-Remission Autograft forAML 25
Page 51 and 52: s o CO s •o « k. 3 Q. P CO l_ O
Page 53: First-Remission Autograft for AML 2
Page 56 and 57:
32 Transplantation in CRI AML Of 24
Page 59 and 60:
Autologous Bone Marrow Transplantat
Page 61 and 62:
ABMT in ALL 37 Table 1. Patient Cha
Page 63 and 64:
ABMT in ALL 39 CRj (N. 16) CRJ+CRJ
Page 65 and 66:
ABMT in ALL 41 (46.5% for ALL and 4
Page 67 and 68:
Studies of High-Dose Intensificatio
Page 69 and 70:
ABMTinCRl 45 Induction V A D C- V A
Page 71:
ABMTin CRI 47 DFS rate for the CBV-
Page 74 and 75:
50 Panel Discussion: Session IA the
Page 76 and 77:
52 Panel Discussion: Session IA DR.
Page 79 and 80:
A Study Design to Determine the Rol
Page 81 and 82:
ABMT In CR2 57 CR INVERSION: 2/22 -
Page 83 and 84:
Page 85 and 86:
ABMT in Acute Nonlymphocytic Leukem
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Transplantation Trial With Marrow T
Page 95 and 96:
ABMTin AML With Monoclonal Antibodi
Page 97 and 98:
ABMT in AML With Monoclonal Antibod
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Chemopurging of Autologous Bone Mar
Page 105 and 106:
Mafosfamlde Purging in Leukemia 81
Page 107 and 108:
Mafosfamide Purging in Leukemia 83
Page 109 and 110:
Page 111:
Page 114 and 115:
90 ABMT in CR2 Pediatric ALL Immuno
Page 116 and 117:
92 ABMT in CR2 Pediatric ALL first
Page 118 and 119:
94 Ex Vivo Marrow Purging with marr
Page 120 and 121:
96 Ex Vivo Marrow Purging BONE MARR
Page 122 and 123:
98 Ex Vivo Marrow Purging reflect t
Page 124 and 125:
700 Conditioning Regimens in AML cy
Page 126 and 127:
102 Conditioning Regimens in AML Ta
Page 129 and 130:
Double CInpurged Autologous Bone Ma
Page 131 and 132:
Double Unpurged ABMT in Leukemias 1
Page 133 and 134:
Double (Jnpurged ABMT in Leukemias
Page 135 and 136:
Double Autografting as Potential Cu
Page 137 and 138:
Double Autografting in Acute Leukem
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Hematopoietic Recovery After Bone M
Page 145 and 146:
Recovery After 4-Hydroperoxycycloph
Page 147:
Recovery After 4-Hydroperoxycycloph
Page 150 and 151:
126 Panel Discussion: Session IB DR
Page 152 and 153:
128 Panel Discussion: Session IB 18
Page 155:
IC. Leukemia Purging/Detection of M
Page 158 and 159:
134 Magnetic Separation of Marrow C
Page 160 and 161:
Page 162 and 163:
Ol O) < c « .o. >» o T3 c « =5
Page 164 and 165:
M I M ! CM CO CO CO CO LO M M CO CO
Page 166 and 167:
Page 168 and 169:
144 Chemopurging leukemic (ALL) pat
Page 170 and 171:
746 Chemopurging isoeffect. On the
Page 172 and 173:
148 Chemopurging Table 4. Ex Vivo P
Page 174 and 175:
750 Chemopurging 5. Kaizer H, Stuar
Page 176 and 177:
152 Merocyanine 540 Marrow Decontam
Page 178 and 179:
Page 180 and 181:
Page 182 and 183:
758 CALLA-Negatiue Clonogenic B-Cel
Page 184 and 185:
160 CALLA-Negatiue Clonogenic B-Cel
Page 187 and 188:
Acetaldophosphamide—A New Stable
Page 189 and 190:
Acetaldophosphamide Ex Vivo Chemoth
Page 191 and 192:
Page 193:
Page 196 and 197:
172 Detecting Residual Disease in B
Page 198 and 199:
174 Detecting Residual Disease in B
Page 201 and 202:
Pharmacological Manipulation to Rev
Page 203 and 204:
Pharmacological Manipulation and Pu
Page 205 and 206:
Page 207 and 208:
Page 209:
Page 213 and 214:
Transient Restoration of Partial Ph
Page 215 and 216:
CO o o o o o •o c co CD È >•!
Page 217 and 218:
CML Chronic Phase Autografting 193
Page 219 and 220:
Mitoxantrone, Cytarabine, and Melph
Page 221:
CML Blast Crisis Autografting 197 c
Page 224 and 225:
200 Autografting in Chronic Granulo
Page 226 and 227:
202 Autografting in Chronic Granulo
Page 229 and 230:
Page 231:
IIA. Hodgkin's Disease
Page 234 and 235:
210 ABMTin Hodgkin's Disease Analys
Page 236 and 237:
212 ABMTin Hodgkin's Disease CR n =
Page 238 and 239:
214 ABMTin Hodgkin's Disease Postmo
Page 240 and 241:
216 ABMTin Hodgkin's Disease progno
Page 242 and 243:
218 CBV and ABMT in Hodgkin s Disea
Page 244 and 245:
220 CBV and ABMT in Hodgkin s Disea
Page 247 and 248:
High-Dose Chemotherapy and Autologo
Page 249 and 250:
Chemotherapy andABMT in Hodgkin's D
Page 251 and 252:
Chemotherapy and ABMTin Hodgkin's D
Page 253 and 254:
Chemotherapy andABMTin Hodgkin s Di
Page 255 and 256:
Treating Advanced Hodgkin's Disease
Page 257 and 258:
ABMT for Advanced Hodgkin's Disease
Page 259:
ABMT for Advanced Hodgkin's Disease
Page 262 and 263:
238 Panel Discussion: Session IIA D
Page 264 and 265:
240 Panel Discussion: Session IIA D
Page 267 and 268:
Recent Results With Salvage Chemoth
Page 269 and 270:
Salvage Chemotherapy for Lymphoma 2
Page 271:
Salvage Chemotherapy for Lymphoma 2
Page 274 and 275:
250 ABMTin Burkitt's Lymphoma (8-10
Page 276 and 277:
252 ABMT in Burkitt's Lymphoma intr
Page 278 and 279:
254 ABMTin Burkitts Lymphoma Table
Page 280 and 281:
256 ABMT in Burkitt's Lymphoma rela
Page 282 and 283:
258 ABMT in Burkitt's Lymphoma DISC
Page 284 and 285:
260 ABMTin Burkitts Lymphoma restri
Page 287 and 288:
Biology and Therapy of Multiple Mye
Page 289 and 290:
Myeloma Biology and Therapy 265 onl
Page 291 and 292:
Myeloma Biology and Therapy 267 res
Page 293 and 294:
Bone Marrow Transplantation in Rela
Page 295 and 296:
(S E o I 9*1 0 ü 41 O) CD ~ i: O)
Page 297 and 298:
BMT in Relapsed Diffuse Large Cell
Page 299 and 300:
Treatment of Malignant Lymphoma at
Page 301:
Transplantation for Malignant Lymph
Page 304 and 305:
280 ABMT Timing in Lymphoma produce
Page 306 and 307:
0) O) .2 '55 o c O) o o Q. c o + +
Page 308 and 309:
284 ABMT Timing in Lymphoma ABMT on
Page 310 and 311:
286 ABMT Timing in Lymphoma abdomin
Page 312 and 313:
« "5 a o « £ a> Z aT in O Q « O
Page 314 and 315:
290 ABMT Timing in Lymphoma Role of
Page 316 and 317:
292 ABMT Timing in Lymphoma inducti
Page 318 and 319:
294 ABMT Timing in Lymphoma Clift R
Page 321 and 322:
Treatment Strategies for Advanced A
Page 323 and 324:
Treatment Strategies for NHL 299 Su
Page 325 and 326:
« E BS « oc c 4> E ai O c CD e 0)
Page 327 and 328:
Treatment Strategies for NHL 303 So
Page 329 and 330:
Treatment Strategies for NHL 305 pa
Page 331 and 332:
Non-Hodgkin's Lymphoma S. Gulati an
Page 333:
Panel Discussion: Session IIB 309 i
Page 337 and 338:
An International Randomized Study o
Page 339 and 340:
Proposed International Adult Lympho
Page 341 and 342:
Page 343 and 344:
Page 345 and 346:
Page 347 and 348:
Page 349 and 350:
Page 351 and 352:
Page 353 and 354:
Page 355 and 356:
Page 357:
Page 360 and 361:
336 International NHL Trial THEORET
Page 362 and 363:
338 International NHL Trial RELAPSE
Page 364 and 365:
340 International NHL Trial ANALYSI
Page 366 and 367:
342 International NHL Trial The ste
Page 368 and 369:
344 Panel Discussion: Session IIC d
Page 371 and 372:
Chemoimmunoseparation of T Lymphoma
Page 373 and 374:
Chemoimmunoseparation of T Lymphoma
Page 375 and 376:
Using a Liquid Cell Culture Assay t
Page 377 and 378:
Burkitt's Lymphoma Purging Assay 35
Page 379 and 380:
Page 381 and 382:
Page 383 and 384:
Comparative Efficiency of an Immuno
Page 385 and 386:
Purging Methods in Burkitt's Lympho
Page 387 and 388:
Purging Methods in Burkitt's Lympho
Page 389 and 390:
Susceptibility of Lymphoid Malignan
Page 391 and 392:
Leukemia Cell Sensitioity to Immuno
Page 393 and 394:
Leukemia Cell Sensitivity to Immuno
Page 395 and 396:
Lymphoma: Purging and Detecting K.
Page 397:
III. Neuroblastoma
Page 400 and 401:
376 ABMT for Neuroblastoma TOXICITY
Page 402 and 403:
378 ABMT for Neuroblastoma 100 Befo
Page 404 and 405:
380 ABMTfor Neuroblastoma modificat
Page 406 and 407:
382 ABMTfor Neuroblastoma Naval Med
Page 408 and 409:
384 ABMT in Metastatic Neuroblastom
Page 410 and 411:
Page 412 and 413:
Page 414 and 415:
Page 417 and 418:
High-Dose Therapy and Unpurged Bone
Page 419 and 420:
Unpurged ABMTfor Neuroblastoma 395
Page 421 and 422:
(Jnpurged ABMT for Neuroblastoma 39
Page 423:
Unpurged ABMT for Neuroblastoma 399
Page 426 and 427:
402 High-Dose Melphalan in Neurobla
Page 428 and 429:
404 High-Dose Melphalan in Neurobla
Page 431 and 432:
Bone Marrow Transplantation in an C
Page 433 and 434:
ABMT in 65 Patients With Neuroblast
Page 435 and 436:
Page 437 and 438:
Page 439 and 440:
ABMTin 65 Patients With Neuroblasto
Page 441:
ABMTin 65 Patients With Neuroblasto
Page 444 and 445:
420 ABMT in Neuroblastoma Group 2
Page 446 and 447:
422 ABMT in Neuroblastoma RESULTS A
Page 449 and 450:
Transplantation for Neuroblastoma U
Page 451 and 452:
Purged Marrow Engraftment in Neurob
Page 453 and 454:
Page 455:
Page 458 and 459:
s o o o i o i - w n . t t i s T - T
Page 460 and 461:
436 Digital Image Analysis System a
Page 462 and 463:
438 Digital Image Analysis System T
Page 464 and 465:
440 Digital Image Analysis System u
Page 467 and 468:
Eliminating Burkitt's Cells From Ex
Page 469 and 470:
Immunomagnetic Purging ofBurkitt's
Page 471 and 472:
Immunomagnetic Purging ofBurkitt's
Page 473 and 474:
Neuroblastoma T. Philip and C. P. R
Page 475 and 476:
Panel Discussion: Session 111 451 w
Page 477:
IV. Breast Cancer
Page 480 and 481:
456 High-Dose Chemotherapy and ABMT
Page 482 and 483:
Page 484 and 485:
Page 486 and 487:
Page 489 and 490:
Strategies in the Treatment of Brea
Page 491 and 492:
Treatment Strategies in Breast Canc
Page 493 and 494:
Page 495 and 496:
Page 497 and 498:
Page 499 and 500:
Phase I and II Studies of High-Dose
Page 501 and 502:
a « O 75 o c Ü co s g c .2 — o
Page 503 and 504:
+ O CM CD CM CO CO O O CM O CM CM 8
Page 505 and 506:
High-Dose Chemotherapy and Autologo
Page 507 and 508:
High-Dose Therapy and ABMT in Breas
Page 509 and 510:
Immunodetection of Breast Carcinoma
Page 511:
Immunodetection of Breast Carcinoma
Page 514 and 515:
490 ABMTfor Breast Cancer initial s
Page 516 and 517:
492 ABMT for Breast Cancer agent gr
Page 518 and 519:
494 ABMT for Breast Cancer approach
Page 521 and 522:
Detection of Occult Breast Cancer C
Page 523 and 524:
Occult Breast Cancer Cells in Marro
Page 525 and 526:
Occult Breast Cancer Cells in Marro
Page 527 and 528:
Breast Cancer E. Frei III and R. Ba
Page 529 and 530:
Panel Discussion: Session IV 505 DR
Page 531:
V. Lung Cancer
Page 534 and 535:
570 Tumor Cell Detection MATERIAL A
Page 536 and 537:
512 Tumor Cell Detection Table 3. I
Page 539 and 540:
High-Dose Etoposide and Cisplatin W
Page 541 and 542:
Etoposide and Cisplatin for Lung Ca
Page 543 and 544:
Page 545:
Page 548 and 549:
524 Panel Discussion: Session V to
Page 550 and 551:
526 Panel Discussion: Session V sma
Page 553:
VI. Melanoma/Sarcoma/Carcinoma
Page 556 and 557:
532 ABMT in Melanoma chemotherapy a
Page 558 and 559:
534 ABMT in Melanoma Table 2. Effec
Page 560 and 561:
536 ABMT in Melanoma with either si
Page 562 and 563:
538 Panel Discussion: Session VI ca
Page 564 and 565:
540 Panel Discussion: Session VI sa
Page 567 and 568:
Intensive Monochemotherapy With Car
Page 569 and 570:
Carmustine and ABMTfor Malignant Gl
Page 571:
Carmustine andABMTfor Malignant Gli
Page 574 and 575:
550 High-Dose Carmustine and Transp
Page 576 and 577:
Page 578 and 579:
Page 580 and 581:
Page 582 and 583:
558 High-Dose Therapy of CHS Glioma
Page 584 and 585:
Page 586 and 587:
Page 589 and 590:
Brain Cancer S. Wolff and G. Herzig
Page 591:
Panel Discussion: Session VII 567 D
Page 595 and 596:
Intensification Regimens for Autolo
Page 597 and 598:
Clinical Intensification Regimens f
Page 599 and 600:
c « O) o in CM -r 1 •«t 00 i -
Page 601 and 602:
Page 603:
Page 606 and 607:
582 Busulfan + Cyclophosphamide in
Page 608 and 609:
Busulfan + Cyclophosphamide in Chil
Page 610 and 611:
Page 612 and 613:
Page 614 and 615:
590 Intensive use of Carmustine Pul
Page 617 and 618:
A Phase II Study of a New Cytoreduc
Page 619 and 620:
BEAM: Cytoreductiue Regimen for Lym
Page 621 and 622:
BEAM: Cytoreductiue Regimen for Lym
Page 623 and 624:
BEAM: Cytoreductlue Regimen for Lym
Page 625 and 626:
Total Body Irradiation, High-Dose C
Page 627 and 628:
Total Body Irradiation, Cytarabine,
Page 629 and 630:
New Regimens K. Antman and M. Syman
Page 631:
IX. Supportive Therapy
Page 634 and 635:
670 Herpesvirus Infections Table 1.
Page 636 and 637:
612 Herpesvirus Infections Table 3.
Page 639 and 640:
Autologous Blood Stem Cell Transpla
Page 641 and 642:
Peripheral Stem Cell Transplantatio
Page 643 and 644:
Page 645 and 646:
Page 647 and 648:
Page 649 and 650:
a c CO TO O O S E => CO "O CO i- t
Page 651 and 652:
3 w •o « C C o ü ü CD < , o E
Page 653 and 654:
Page 655 and 656:
Page 657 and 658:
Toxic Deaths After Autologous Bone
Page 659 and 660:
Toxic Deaths in ABMT 635 RESULTS Fi
Page 661 and 662:
Toxic Deaths in ABMT 63 7 Patient/
Page 663 and 664:
Infectious Complications of Autolog
Page 665 and 666:
Infectious Complications of ABMT Ta
Page 667 and 668:
Infectious Complications ofABMT 643
Page 669:
Infectious Complications ofABMT 645
Page 672 and 673:
648 Infections in ABMT MATERIAL AND
Page 674 and 675:
650 Infections in ABMT Category Tab
Page 676 and 677:
652 Infections in ABMT been found,
Page 678 and 679:
654 Antibiotics in Cancer Patients
Page 680 and 681:
656 Antibiotics in Cancer Patients
Page 683 and 684:
The Empiric Use of Amphotericin B f
Page 685 and 686:
Amphotericin B for Neutropenie Feue
Page 687 and 688:
Amphotericin B for Neutropenie Feve
Page 689 and 690:
The Role of Intravenous Immune Glob
Page 691 and 692:
Mg in ABMT 667 broken down; antigen
Page 693 and 694:
The Possible Therapeutic Value of N
Page 695 and 696:
Natural Killer Cells and Transplant
Page 697:
Natural Killer Cells and Transplant
Page 700:
676 Transplantation of Circulating
Page 703:
Transplantation of Circulating Stem
Page 706 and 707:
682 Peripheral Stem Cell Transplant
Page 708 and 709:
684 Peripheral Stem Cell Transplant
Page 711 and 712:
Autologous Transplantation Using Pe
Page 713 and 714:
Peripheral Blood Stem Cell Transpla
Page 715 and 716:
Peripheral Blood Stem Cell Transpla
Page 717 and 718:
Bronchoscopic Examination and Bronc
Page 719 and 720:
Bronchoscopy in Marrow Transplantat
Page 721 and 722:
Effect of Interleukin 2 on T Lympho
Page 723 and 724:
c c 4) "5 Q. Ss •o 3 35 (A U «5
Page 725 and 726:
T Lymphocyte CFU After ABMT 701 Six
Page 727:
T Lymphocyte CFCJ After ABMT 703 no
Page 730 and 731:
706 Panel Discussion: Session IX se
Page 733 and 734:
Expression of Human Adenosine Deami
Page 735 and 736:
Human ADA in Monkeys 711 to the SAX
Page 737 and 738:
Human ADA in Monkeys 713 4 were nev
Page 739 and 740:
Human ADA in Monkeys 715 tuted marr
Page 741 and 742:
Electric Field-Mediated DNA Transfe
Page 743 and 744:
Page 745:
Page 748 and 749:
724 Aberrant Gene Expression in AML
Page 750 and 751:
Page 752 and 753:
Page 755 and 756:
Clonal Detection of Remission by Re
Page 757 and 758:
Clonal Detection of Remission 733 c
Page 759 and 760:
Clonal Detection of Remission 3 735
Page 761:
XI. Summary
Page 764 and 765:
740 Summary administration of the a
Page 766 and 767:
742 Summary particularly apparent i
Page 768 and 769:
744 Summary limited occurrence of t
Page 771 and 772:
Concluding Remarks Karel A. Dicke I
Page 773 and 774:
Contributors and Participants Zora
Page 775 and 776:
Contributors and Participants 751 M
Page 777 and 778:
Contributors and Participants 753 A
Page 779 and 780:
Contributors and Participants 755 R
Page 781 and 782:
Contributors and Participants 757 M
Page 783 and 784:
Contributors and Participants Leona
Page 785 and 786:
Contributors and Participants 761 L
Page 787 and 788:
Contributors and Participants 763 B
Page 789 and 790:
Contributors and Participants 765 J
Page 791 and 792:
Page 793 and 794:
Contributors and Participants 769 B
Page 795 and 796:
Contributors and Participants 771 G
Page 797 and 798:
Contributors and Participants 773 A
Page 799 and 800:
show all

Autologous Bone Marrow Transplantation - Blog Science Connections

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?